IL205246A0 - Methods and compositions for diagnostic use in cancer patients - Google Patents

Methods and compositions for diagnostic use in cancer patients

Info

Publication number
IL205246A0
IL205246A0 IL205246A IL20524610A IL205246A0 IL 205246 A0 IL205246 A0 IL 205246A0 IL 205246 A IL205246 A IL 205246A IL 20524610 A IL20524610 A IL 20524610A IL 205246 A0 IL205246 A0 IL 205246A0
Authority
IL
Israel
Prior art keywords
compositions
methods
cancer patients
diagnostic use
diagnostic
Prior art date
Application number
IL205246A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL205246A0 publication Critical patent/IL205246A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL205246A 2007-11-09 2010-04-22 Methods and compositions for diagnostic use in cancer patients IL205246A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98688407P 2007-11-09 2007-11-09
PCT/US2008/082456 WO2009061800A2 (en) 2007-11-09 2008-11-05 Methods and compositions for diagnostic use in cancer patients

Publications (1)

Publication Number Publication Date
IL205246A0 true IL205246A0 (en) 2010-12-30

Family

ID=40342593

Family Applications (1)

Application Number Title Priority Date Filing Date
IL205246A IL205246A0 (en) 2007-11-09 2010-04-22 Methods and compositions for diagnostic use in cancer patients

Country Status (13)

Country Link
US (2) US20090123930A1 (enExample)
EP (1) EP2222874A2 (enExample)
JP (1) JP2011502513A (enExample)
KR (1) KR20100095571A (enExample)
CN (1) CN101910416A (enExample)
AU (1) AU2008324782A1 (enExample)
BR (1) BRPI0817158A2 (enExample)
CA (1) CA2703258A1 (enExample)
IL (1) IL205246A0 (enExample)
MX (1) MX2010005057A (enExample)
RU (1) RU2010123381A (enExample)
WO (1) WO2009061800A2 (enExample)
ZA (1) ZA201002808B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2766403A1 (en) * 2009-07-13 2011-01-20 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
WO2011033006A1 (en) * 2009-09-17 2011-03-24 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
JP2013538338A (ja) * 2010-07-19 2013-10-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗癌治療への応答可能性の増大した患者を同定する方法
SG10201505593VA (en) * 2010-07-19 2015-09-29 Hoffmann La Roche Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
BR112013031019A2 (pt) * 2011-06-02 2017-03-21 Almac Diagnostics Ltd teste diagnóstico molecular para câncer
EP2802346B1 (en) * 2012-01-13 2018-09-12 F.Hoffmann-La Roche Ag Biological markers for identifying patients for treatment with vegf antagonists
KR20150024342A (ko) * 2012-06-26 2015-03-06 에프. 호프만-라 로슈 아게 유방암을 치료하기 위한 베바시주맙 조합 요법에 대한 혈장 바이오마커
US11091809B2 (en) 2012-12-03 2021-08-17 Almac Diagnostic Services Limited Molecular diagnostic test for cancer
SG11201602019XA (en) * 2013-09-17 2016-04-28 Agency Science Tech & Res Multigene assay for prognosis of renal cancer
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
EP3230498B1 (en) * 2014-12-09 2023-01-18 Merck Sharp & Dohme LLC System and methods for deriving gene signature biomarkers of response to pd-1 antagonists
KR101903522B1 (ko) * 2015-11-25 2018-11-23 한국전자통신연구원 다차원 건강데이터에 대한 유사사례 검색 방법 및 그 장치
TW202528738A (zh) * 2023-11-09 2025-07-16 昇捷生物科技股份有限公司 基於α-1抗胰蛋白酶生物標記物之癌症檢測方法及套組

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027216A1 (en) * 2001-07-02 2003-02-06 Kiernan Urban A. Analysis of proteins from biological fluids using mass spectrometric immunoassay
CA2604549A1 (en) * 2005-04-13 2006-10-19 Oncotest Gmbh Gene expression profiles being predictive for the response of tumors to pharmaceutically effective compounds
CA2648106A1 (en) * 2006-03-31 2007-11-01 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy

Also Published As

Publication number Publication date
KR20100095571A (ko) 2010-08-31
EP2222874A2 (en) 2010-09-01
US20110151468A1 (en) 2011-06-23
CN101910416A (zh) 2010-12-08
ZA201002808B (en) 2011-07-27
MX2010005057A (es) 2010-05-19
CA2703258A1 (en) 2009-05-14
JP2011502513A (ja) 2011-01-27
US20090123930A1 (en) 2009-05-14
AU2008324782A1 (en) 2009-05-14
RU2010123381A (ru) 2011-12-20
WO2009061800A2 (en) 2009-05-14
WO2009061800A3 (en) 2009-07-16
BRPI0817158A2 (pt) 2015-04-14

Similar Documents

Publication Publication Date Title
IL213410A0 (en) Methods and compositions for diagnostic use in cancer patients
ZA201002808B (en) Methods and compositions for diagnostic use in cancer patients
EP2038041A4 (en) THERAPEUTIC COMPOUNDS AND THEIR USE AGAINST CANCER
EP2180873A4 (en) THERAPEUTIC DENTAL COMPOSITION AND RELATED METHODS
SI2200431T1 (sl) Sestave in metode za zdravljenje raka
PL3009148T3 (pl) Kompozycje oraz sposoby leczenia i diagnozowania nowotworu
GB0708761D0 (en) Improvements in and relating to medical instruments
EP2125887A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
IL217748A0 (en) Methods and compositions for diagnostics use in cancer patients
EP2155249A4 (en) COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER
EP2148675A4 (en) ANTI-CANCER FOR THE DIAGNOSIS AND TREATMENT OF CANCER
PL2320900T3 (pl) Opioidy do zastosowania w leczeniu opornych pacjentów onkologicznych
GB2459076B (en) Improvements in and relating to medical devices
EP2198041A4 (en) METHOD AND COMPOSITION FOR CANCER DIAGNOSIS AND TREATMENT
IL206189A0 (en) Compound for use in the treatment of cancer
EP2222689A4 (en) THERAPEUTIC AND DIAGNOSTIC COMPOUNDS
EP2018178A4 (en) ADMINISTRATION OF AN AGONIST-ANTAGONIST COMPLEX TO PATIENTS WITH OPIOID DEPENDENCE
GB0821335D0 (en) Compositions and methods for reducing macrovascular complications in diabetic patients
GB2467494B (en) Materials and methods for medical imaging
GB0813352D0 (en) Cancer treatment and test
GB2441116B (en) Improvements in and relating to medical apparatus
SI3067054T1 (sl) Novi sestavki in postopki za zdravljenje raka
PT3067054T (pt) Novas composições e métodos para o tratamento de cancro
GB0819103D0 (en) Raphaine compounds and their use in therapy